Selux Diagnostics
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
👥11-50
📍Watertown
Selux Diagnostics
About Selux Diagnostics
Fighting antimicrobial resistance with a Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients.
Selux Diagnostics news and updates
Selux Diagnostics, Inc received financing of $50M in Series C financing on Feb 28th 22'.
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation Phenotyping (NGP) rapid Antimicrobial Susceptibility Testing (AST) platform.
Jan 1, 2022 | prnewswire.comSelux Diagnostics, Inc is developing NGP platform
Selux is developing an NGP platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed.
Jan 1, 2022 | valdostadailytimes.com